155 related articles for article (PubMed ID: 1310099)
1. High frequency of myelomonocytic tumors in aging E mu L-myc transgenic mice.
Möröy T; Fisher PE; Lee G; Achacoso P; Wiener F; Alt FW
J Exp Med; 1992 Feb; 175(2):313-22. PubMed ID: 1310099
[TBL] [Abstract][Full Text] [Related]
2. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice.
Möröy T; Verbeek S; Ma A; Achacoso P; Berns A; Alt F
Oncogene; 1991 Nov; 6(11):1941-8. PubMed ID: 1658705
[TBL] [Abstract][Full Text] [Related]
3. IgH enhancer deregulated expression of L-myc: abnormal T lymphocyte development and T cell lymphomagenesis.
Möröy T; Fisher P; Guidos C; Ma A; Zimmerman K; Tesfaye A; DePinho R; Weissman I; Alt FW
EMBO J; 1990 Nov; 9(11):3659-66. PubMed ID: 2120050
[TBL] [Abstract][Full Text] [Related]
4. IgH enhancer-mediated deregulation of N-myc gene expression in transgenic mice: generation of lymphoid neoplasias that lack c-myc expression.
Dildrop R; Ma A; Zimmerman K; Hsu E; Tesfaye A; DePinho R; Alt FW
EMBO J; 1989 Apr; 8(4):1121-8. PubMed ID: 2501083
[TBL] [Abstract][Full Text] [Related]
5. The transgenic window on lymphoid malignancy.
Adams JM; Harris AW; Vaux DL; Alexander WS; Rosenbaum H; Klinken SP; Strasser A; Bath ML; McNeall J; Cory S
Princess Takamatsu Symp; 1989; 20():297-309. PubMed ID: 2518688
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice.
Lovec H; Grzeschiczek A; Kowalski MB; Möröy T
EMBO J; 1994 Aug; 13(15):3487-95. PubMed ID: 8062825
[TBL] [Abstract][Full Text] [Related]
7. H-2/myc, E mu/myc, and c-myc transgenic mice: potent sources of early hematopoietic cell lines.
Roland J; Morello D
Cell Growth Differ; 1993 Nov; 4(11):891-900. PubMed ID: 8297795
[TBL] [Abstract][Full Text] [Related]
8. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV.
Zörnig M; Grzeschiczek A; Kowalski MB; Hartmann KU; Möröy T
Oncogene; 1995 Jun; 10(12):2397-401. PubMed ID: 7784089
[TBL] [Abstract][Full Text] [Related]
9. Strain-dependency of chromosomal abnormalities in lymphomas developed in E mu-myc transgenic mice.
Akagi K; Yamamura K
Jpn J Cancer Res; 2001 May; 92(5):499-505. PubMed ID: 11376558
[TBL] [Abstract][Full Text] [Related]
10. Immunologic competence of B cells subjected to constitutive c-myc oncogene expression in immunoglobulin heavy chain enhancer myc transgenic mice.
Vaux DL; Adams JM; Alexander WS; Pike BL
J Immunol; 1987 Dec; 139(11):3854-60. PubMed ID: 2445821
[TBL] [Abstract][Full Text] [Related]
11. Expression of the c-myc oncogene under control of an immunoglobulin enhancer in E mu-myc transgenic mice.
Alexander WS; Schrader JW; Adams JM
Mol Cell Biol; 1987 Apr; 7(4):1436-44. PubMed ID: 3037318
[TBL] [Abstract][Full Text] [Related]
12. Conditional expression and oncogenicity of c-myc linked to a CD2 gene dominant control region.
Stewart M; Cameron E; Campbell M; McFarlane R; Toth S; Lang K; Onions D; Neil JC
Int J Cancer; 1993 Apr; 53(6):1023-30. PubMed ID: 8473043
[TBL] [Abstract][Full Text] [Related]
13. Selection for c-myc integration sites in polyclonal T-cell lymphomas.
Broussard DR; Mertz JA; Lozano M; Dudley JP
J Virol; 2002 Mar; 76(5):2087-99. PubMed ID: 11836386
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of E mu-myc transgenic mice.
Jacobsen KA; Prasad VS; Sidman CL; Osmond DG
Blood; 1994 Oct; 84(8):2784-94. PubMed ID: 7522642
[TBL] [Abstract][Full Text] [Related]
15. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
[TBL] [Abstract][Full Text] [Related]
16. Origin of histiocyte-like cells and multinucleated giant cells in malignant fibrous histiocytoma: neoplastic or reactive?
Hatano H; Tokunaga K; Ogose A; Imaizumi S; Hayami T; Yamagiwa H; Hotta T; Endo N; Takahashi HE; Naito M
Pathol Int; 1999 Jan; 49(1):14-22. PubMed ID: 10227720
[TBL] [Abstract][Full Text] [Related]
17. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
18. Functional homology between N-myc and c-myc in murine plasmacytomagenesis: plasmacytoma development in N-myc transgenic mice.
Wang Y; Sugiyama H; Axelson H; Panda CK; Babonits M; Ma A; Steinberg JM; Alt FW; Klein G; Wiener F
Oncogene; 1992 Jun; 7(6):1241-7. PubMed ID: 1375720
[TBL] [Abstract][Full Text] [Related]
19. Increased transcription of the E mu-myc transgene and mRNA stabilisation produce only a modest elevation in Myc protein.
Colley SM; Tilbrook PA; Klinken SP
Oncogene; 1997 Jun; 14(22):2735-9. PubMed ID: 9178772
[TBL] [Abstract][Full Text] [Related]
20. Transgenic rabbits with lymphocytic leukemia induced by the c-myc oncogene fused with the immunoglobulin heavy chain enhancer.
Knight KL; Spieker-Polet H; Kazdin DS; Oi VT
Proc Natl Acad Sci U S A; 1988 May; 85(9):3130-4. PubMed ID: 2834733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
